Over the forecast period, the global market for monoclonal antibody therapies is anticipated to rise as these drugs are used to treat a variety of diseases. For instance, the monoclonal antibody therapy has lately emerged as one of the primary modalities for the treatment of cancer, according to a report released by the National Centre for Biotechnology Information (NCBI) in July 2020. The necessity for monoclonal antibody therapies in the treatment of infectious disorders is likely to fuel the market for these drugs during the next years due to the rising prevalence of these diseases. Infectious infections were the leading diagnosis in 3.2 million emergency department visits on January 25, 2023, according to a study released by the Centres for Disease Control and Prevention (CDC). Over the course of the forecast period, North America is anticipated to have a commanding position in the global market for monoclonal antibody therapies. Due to the rising incidence of autoimmune illnesses in the continent, North America currently owns a 45.1% market share.
The Coherent Market Insights estimates that the market for Therapeutic Monoclonal Antibodies is anticipated to reach US$ 205,385.6 million in 2023 and is projected to grow at a CAGR of 12.69% from 2023 to 2030.
Major Players in the Monoclonal Antibody Therapeutics Industry:
1. Novartis AG,
The company was founded in March 1996 and has its main offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Novartis provides coverage for all types of medications, including authorization, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including managing, advertising, operations, and research.
2. Pfizer Inc.,
The company was established in 1849, and Manhattan, New York City, is where its corporate headquarters are situated. Through the creation of pharmaceuticals and vaccines, Pfizer seeks to enhance the fields of immunology, cancer, the heart, endocrinology, and neurology. In October 2022, the business successfully acquired Biohaven Pharma's calcitonin gene-related peptide programmes. Pfizer purchased Amplyx Pharmaceuticals in April 2021, which included the rights to the antifungal drug fosmanogepix (APX001).
3. Sanofi
The business was established in 1973 and is based in Paris, France. The company provides drugs, generic medications, food supplements, cosmetics, and medical devices for conditions like cancer, cardiology, gynaecology, and diabetes. The business declared in March 2023 that it will buy Provention Bio and its pipeline of type 1 diabetic treatments.
4. Bristol-Myers Squibb Company
It was founded in 1887, and it is headquartered in New York, USA. The company makes prescription medications and biologics for a variety of illnesses, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. BMS announced that it would buy Turning Point Therapeutics Inc. for $4.1 billion in cash in June 2022.
5. Merck & Co., Inc.
The business was founded in 1668, and Rahway, New Jersey is where its headquarters are. Merck produces medicines, vaccines, biologic therapies, and things for animal health. After paying an undisclosed sum for the cattle management company Vence, the company announced in September 2022 that it will merge with Merck Animal Health. In February 2021, Merck Animal Health acquired PrognostiX Poultry.
6. F. Hoffmann-La Roche Ltd.
The company was founded in 1896 and has its headquarters in Basel, Switzerland. The business provides cancer and transplant drugs, as well as in-vitro diagnostics. Roche declared in March 2021 that it would buy GenMark Diagnostics for $1.8 billion. In September 2021, the business revealed that it would buy the German biotech firm TIB Molbiol in order to grow its molecular diagnostics division.
7. AstraZeneca plc
The company was established in 1999, and its headquarters are in Cambridge, United Kingdom. Treatments for neurological, respiratory, inflammatory, viral, and heart problems are among its product offerings. In January 2023, AstraZeneca announced that it would purchase CinCor Pharma for $1.8 billion. The company announced in July 2022 that it would extend its portfolio of blood cancer drugs by purchasing TeneoTwo for up to $1.3 billion.
8. Thermo Fisher Scientific
The business was started in 1956 and has its headquarters in Waltham, Massachusetts, United States. Thermo Fisher Scientific, Inc. produces chemicals, consumables, and scientific equipment. The acquisition of PPD, Inc. by Thermo Fisher Scientific was announced in April 2021. Thermo Fisher Scientific said in January 2021 that it had purchased Henogen SA, a producer of viral vectors based in Belgium, from Groupe Novasep SAS for €725 million in cash.
Definition: Monoclonal antibodies (mAbs) are a type of immunotherapy that are used to bind monospecifically to particular cells or proteins. The goal of this therapy is to activate the patient's immune system to fight such cells.
